Skip to main content

Table 4 In vivo animal study details

From: Development, optimization and pharmacokinetic evaluation of biphasic extended-release osmotic drug delivery system of trospium chloride for promising application in treatment of overactive bladder

Group Number of samples Time points (h) Study days Blood volume collected Anticoagulant
Male Female
Trospium chloride ER tablets 60 mg OROS tablets (test product) 03 00 0 h before administration and 1, 3, 5, 8, 10, 12, 14, 16, 18, 21, 24 h after administration 1 day 0.7 mL K3 EDTA
Sanctura® XR capsules 60 mg (innovator CAPSULES) (reference product) 02 01 0 h before administration and 1, 3, 5, 8, 10, 12, 14, 16, 18, 21, 24 h after administration 1 day 0.7 mL K3 EDTA